CN115252768A - Composition for improving male reproductive capacity, preparation method and application - Google Patents
Composition for improving male reproductive capacity, preparation method and application Download PDFInfo
- Publication number
- CN115252768A CN115252768A CN202211081171.2A CN202211081171A CN115252768A CN 115252768 A CN115252768 A CN 115252768A CN 202211081171 A CN202211081171 A CN 202211081171A CN 115252768 A CN115252768 A CN 115252768A
- Authority
- CN
- China
- Prior art keywords
- composition
- bacillus subtilis
- parts
- male reproductive
- improving male
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 46
- 230000001850 reproductive effect Effects 0.000 title claims abstract description 37
- 238000002360 preparation method Methods 0.000 title abstract description 15
- 244000063299 Bacillus subtilis Species 0.000 claims abstract description 48
- 235000014469 Bacillus subtilis Nutrition 0.000 claims abstract description 48
- 241001264174 Cordyceps militaris Species 0.000 claims abstract description 21
- 101710196208 Fibrinolytic enzyme Proteins 0.000 claims abstract description 21
- 241000168517 Haematococcus lacustris Species 0.000 claims abstract description 20
- 235000009496 Juglans regia Nutrition 0.000 claims abstract description 20
- 235000020234 walnut Nutrition 0.000 claims abstract description 20
- 229940012957 plasmin Drugs 0.000 claims abstract description 17
- 239000002994 raw material Substances 0.000 claims abstract description 15
- 235000007164 Oryza sativa Nutrition 0.000 claims abstract description 14
- 235000009566 rice Nutrition 0.000 claims abstract description 14
- 235000013305 food Nutrition 0.000 claims abstract description 6
- 238000004321 preservation Methods 0.000 claims abstract description 6
- 238000000855 fermentation Methods 0.000 claims description 20
- 230000004151 fermentation Effects 0.000 claims description 20
- 241000758789 Juglans Species 0.000 claims description 19
- 241000209094 Oryza Species 0.000 claims description 13
- 230000035558 fertility Effects 0.000 claims description 9
- 238000001035 drying Methods 0.000 claims description 8
- 238000002156 mixing Methods 0.000 claims description 8
- 239000001963 growth medium Substances 0.000 claims description 7
- 239000007788 liquid Substances 0.000 claims description 7
- JEBFVOLFMLUKLF-IFPLVEIFSA-N Astaxanthin Natural products CC(=C/C=C/C(=C/C=C/C1=C(C)C(=O)C(O)CC1(C)C)/C)C=CC=C(/C)C=CC=C(/C)C=CC2=C(C)C(=O)C(O)CC2(C)C JEBFVOLFMLUKLF-IFPLVEIFSA-N 0.000 claims description 6
- 235000013793 astaxanthin Nutrition 0.000 claims description 6
- MQZIGYBFDRPAKN-ZWAPEEGVSA-N astaxanthin Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)[C@@H](O)CC1(C)C MQZIGYBFDRPAKN-ZWAPEEGVSA-N 0.000 claims description 6
- 229940022405 astaxanthin Drugs 0.000 claims description 6
- 239000001168 astaxanthin Substances 0.000 claims description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 5
- CNNRPFQICPFDPO-UHFFFAOYSA-N octacosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCO CNNRPFQICPFDPO-UHFFFAOYSA-N 0.000 claims description 4
- KQLDDLUWUFBQHP-UHFFFAOYSA-N Cordycepin Natural products C1=NC=2C(N)=NC=NC=2N1C1OCC(CO)C1O KQLDDLUWUFBQHP-UHFFFAOYSA-N 0.000 claims description 3
- 239000012880 LB liquid culture medium Substances 0.000 claims description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 3
- 238000001816 cooling Methods 0.000 claims description 3
- OFEZSBMBBKLLBJ-BAJZRUMYSA-N cordycepin Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)C[C@H]1O OFEZSBMBBKLLBJ-BAJZRUMYSA-N 0.000 claims description 3
- OFEZSBMBBKLLBJ-UHFFFAOYSA-N cordycepine Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(CO)CC1O OFEZSBMBBKLLBJ-UHFFFAOYSA-N 0.000 claims description 3
- 238000011081 inoculation Methods 0.000 claims description 3
- 238000000034 method Methods 0.000 claims description 3
- 238000001471 micro-filtration Methods 0.000 claims description 3
- 239000001301 oxygen Substances 0.000 claims description 3
- 229910052760 oxygen Inorganic materials 0.000 claims description 3
- 238000001694 spray drying Methods 0.000 claims description 3
- 230000001954 sterilising effect Effects 0.000 claims description 3
- 238000000108 ultra-filtration Methods 0.000 claims description 3
- 229960002666 1-octacosanol Drugs 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 238000012805 post-processing Methods 0.000 claims description 2
- 235000013402 health food Nutrition 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 229940127557 pharmaceutical product Drugs 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 20
- 239000003098 androgen Substances 0.000 abstract description 8
- 230000002195 synergetic effect Effects 0.000 abstract description 7
- 230000004060 metabolic process Effects 0.000 abstract description 5
- 230000017531 blood circulation Effects 0.000 abstract description 4
- 230000036039 immunity Effects 0.000 abstract description 4
- 239000000463 material Substances 0.000 abstract description 4
- 239000013589 supplement Substances 0.000 abstract description 2
- 240000007049 Juglans regia Species 0.000 abstract 1
- 240000007594 Oryza sativa Species 0.000 abstract 1
- 241000700159 Rattus Species 0.000 description 28
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 12
- 230000000052 comparative effect Effects 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- 208000031975 Yang Deficiency Diseases 0.000 description 9
- 230000006872 improvement Effects 0.000 description 9
- 210000001550 testis Anatomy 0.000 description 9
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 8
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 8
- 229940028334 follicle stimulating hormone Drugs 0.000 description 8
- 102000009151 Luteinizing Hormone Human genes 0.000 description 7
- 108010073521 Luteinizing Hormone Proteins 0.000 description 7
- 238000011161 development Methods 0.000 description 7
- 230000018109 developmental process Effects 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 229940040129 luteinizing hormone Drugs 0.000 description 7
- 230000019100 sperm motility Effects 0.000 description 7
- 229940079593 drug Drugs 0.000 description 6
- 229960003604 testosterone Drugs 0.000 description 6
- 238000001914 filtration Methods 0.000 description 5
- 210000000056 organ Anatomy 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 210000000952 spleen Anatomy 0.000 description 5
- 210000001541 thymus gland Anatomy 0.000 description 4
- 244000068988 Glycine max Species 0.000 description 3
- 235000010469 Glycine max Nutrition 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 208000008589 Obesity Diseases 0.000 description 3
- 239000001888 Peptone Substances 0.000 description 3
- 108010080698 Peptones Proteins 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000000918 epididymis Anatomy 0.000 description 3
- 201000010063 epididymitis Diseases 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 235000020824 obesity Nutrition 0.000 description 3
- 235000019319 peptone Nutrition 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 210000001625 seminal vesicle Anatomy 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 201000010653 vesiculitis Diseases 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 208000010228 Erectile Dysfunction Diseases 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 238000007664 blowing Methods 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 230000005670 electromagnetic radiation Effects 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 229940011871 estrogen Drugs 0.000 description 2
- 239000000262 estrogen Substances 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 210000004392 genitalia Anatomy 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 201000001881 impotence Diseases 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 210000004995 male reproductive system Anatomy 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000010298 pulverizing process Methods 0.000 description 2
- 238000011552 rat model Methods 0.000 description 2
- 210000000582 semen Anatomy 0.000 description 2
- 230000036299 sexual function Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 230000000920 spermatogeneic effect Effects 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 1
- RQOCXCFLRBRBCS-UHFFFAOYSA-N (22E)-cholesta-5,7,22-trien-3beta-ol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CCC(C)C)CCC33)C)C3=CC=C21 RQOCXCFLRBRBCS-UHFFFAOYSA-N 0.000 description 1
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 235000019750 Crude protein Nutrition 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 230000007035 DNA breakage Effects 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- DNVPQKQSNYMLRS-NXVQYWJNSA-N Ergosterol Natural products CC(C)[C@@H](C)C=C[C@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@@H]3CC[C@]12C DNVPQKQSNYMLRS-NXVQYWJNSA-N 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000168525 Haematococcus Species 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 208000029549 Muscle injury Diseases 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010036049 Polycystic ovaries Diseases 0.000 description 1
- 201000001880 Sexual dysfunction Diseases 0.000 description 1
- 108090000787 Subtilisin Proteins 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- PFRQBZFETXBLTP-UHFFFAOYSA-N Vitamin K2 Natural products C1=CC=C2C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C(=O)C2=C1 PFRQBZFETXBLTP-UHFFFAOYSA-N 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229940030486 androgens Drugs 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 239000002518 antifoaming agent Substances 0.000 description 1
- 210000001142 back Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- DNVPQKQSNYMLRS-SOWFXMKYSA-N ergosterol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H](CC[C@]3([C@H]([C@H](C)/C=C/[C@@H](C)C(C)C)CC[C@H]33)C)C3=CC=C21 DNVPQKQSNYMLRS-SOWFXMKYSA-N 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 230000004720 fertilization Effects 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000013505 freshwater Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000003163 gonadal steroid hormone Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 229940010073 hydrocortisone injection Drugs 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000011272 imaginal disc-derived genitalia development Effects 0.000 description 1
- 230000008407 joint function Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000002332 leydig cell Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- DKHGMERMDICWDU-GHDNBGIDSA-N menaquinone-4 Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)=C(C)C(=O)C2=C1 DKHGMERMDICWDU-GHDNBGIDSA-N 0.000 description 1
- 230000037323 metabolic rate Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 230000008722 morphological abnormality Effects 0.000 description 1
- 208000013465 muscle pain Diseases 0.000 description 1
- 125000001802 myricyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229960002715 nicotine Drugs 0.000 description 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 201000010065 polycystic ovary syndrome Diseases 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 239000004170 rice bran wax Substances 0.000 description 1
- 235000019384 rice bran wax Nutrition 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 231100000872 sexual dysfunction Toxicity 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 210000004336 spermatogonium Anatomy 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009044 synergistic interaction Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 235000019143 vitamin K2 Nutrition 0.000 description 1
- 239000011728 vitamin K2 Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/484—Plasmin (3.4.21.7)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L31/00—Edible extracts or preparations of fungi; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/02—Algae
- A61K36/05—Chlorophycota or chlorophyta (green algae), e.g. Chlorella
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/062—Ascomycota
- A61K36/066—Clavicipitaceae
- A61K36/068—Cordyceps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/52—Juglandaceae (Walnut family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Mycology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Nutrition Science (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Reproductive Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gynecology & Obstetrics (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention provides a composition for improving male reproductive capacity, a preparation method and application, and belongs to the technical field of bioengineering. The health-care food is prepared from the following raw materials in parts by weight: 10-30 parts of bacillus subtilis fibrinolytic enzyme, 5-15 parts of haematococcus pluvialis, 3-10 parts of walnut kernel extract, 3-10 parts of cordyceps militaris extract and 0.3-0.5 part of rice bran fatty alkanol; the Bacillus subtilis plasmin is prepared by fermenting a strain Bacillus subtilis QK02, the strain is preserved in China Center for Type Culture Collection (CCTCC) with the preservation number of M203078. The bacillus subtilis fibrinolytic enzyme composition with the effect of improving the male reproductive capacity, provided by the invention, reasonably combines edible and pharmaceutical food materials, has a remarkable synergistic effect, promotes blood circulation and metabolism of a human body, eliminates fatigue, supplements androgen, and obviously improves the immunity of the human body.
Description
Technical Field
The invention relates to the technical field of bioengineering, in particular to a composition for improving male reproductive capacity, a preparation method and application thereof.
Background
Along with the improvement of living standard of people, the health consciousness of people is gradually improved. However, the modern people are influenced by various aspects such as the change of dietary structure, the acceleration of life rhythm, psychological and environmental factors, obesity and the like, and the phenomenon of the decline of male reproductive capacity occurs. At present, the blood testosterone level of young men is generally low, the incidence rate of sexual dysfunction is increased, and the testosterone level and the sexual function of young men are often inferior to those of old men aged 50-70 years old. Seriously affecting the quality of life and the happiness index of young men.
The phenomenon of a general decline in male reproductive capacity has attracted the attention of researchers. Epidemiological studies have shown that persistent excess electromagnetic radiation is apt to damage the testes, causing male sexual and reproductive dysfunction. Electromagnetic radiation also reduces androgen levels in males, disrupting male sexual function, and causing diseases in vital organs associated with androgens. The environmental estrogen is mainly bisphenol a. Its toxic effects mainly damage the male reproductive system and directly affect male fertility. The nicotine can cause DNA breakage of spermatogenic cells (spermatogonium and spermatocyte) of a male reproductive system, promote testicular interstitial cells and support apoptosis; the sperm is caused to have morphological abnormality, so that the sperm movement capability is reduced, and the fertilization process is hindered; promoting sperm apoptosis and reducing sperm activity. Hyperglycemia can increase the oxidative stress of sperm, which in turn can impair sperm DNA integrity, ultimately resulting in decreased fertility. Hyperlipidemia has adverse effects on sperm function, and high cholesterol and high phospholipid often cause incomplete structure of sperm acrosome and head end. Obesity can also induce a number of problems affecting reproductive performance, such as Erectile Dysfunction (ED), polycystic ovary fat, androgen serum Total Testosterone (TT), low levels of Free Testosterone (FT), increased estrogen, and the like.
Drugs for the treatment of male reproductive capacity are mainly treated by androgen supplementation and inhibitors. Although the inhibitor drugs have good curative effect, some adverse reactions, mainly including headache, nausea, dry mouth and diarrhea, can occur after the inhibitor drugs are taken. Has great side effect and is easy to relapse after stopping taking the medicine.
The bacillus subtilis fibrinolytic enzyme is prepared by taking soybean peptone as a raw material and performing bacillus subtilis liquid fermentation, concentration and drying, and various physiological active substances including a large amount of bacillus subtilis fibrinolytic enzyme, vitamins and the like are generated in the fermentation process. Has effects in dissolving fibrin and thrombi, dissolving Chen Shuan plaque, reducing blood lipid and blood sugar, promoting blood circulation and metabolism, relieving fatigue, and enhancing immunity. However, at present, there is no report that a composition which takes bacillus subtilis plasmin as a main component, is reasonable in matching and high in activity is applied to the field of health care products with the effect of improving male reproductive capacity.
Disclosure of Invention
The invention aims to provide a composition for improving male reproductive capacity, a preparation method and application, and the composition is prepared by reasonably mixing edible and edible materials, has a remarkable synergistic effect, promotes blood circulation and metabolism of a human body, eliminates fatigue, supplements androgen and obviously improves human immunity.
The technical scheme of the invention is realized as follows:
the invention provides a composition for improving male reproductive capacity, which is prepared from the following raw materials in parts by weight: 10-30 parts of bacillus subtilis fibrinolytic enzyme, 5-15 parts of haematococcus pluvialis, 3-10 parts of walnut kernel extract, 3-10 parts of cordyceps militaris extract and 0.3-0.5 part of rice bran fatty alkanol; the Bacillus subtilis plasmin is prepared by fermenting a strain Bacillus subtilis QK02, the strain is preserved in China Center for Type Culture Collection (CCTCC) with the preservation number of M203078.
As a further improvement of the invention, the Bacillus subtilis plasmin is prepared by fermenting a strain Bacillus subtilis QK02, centrifuging, concentrating and drying.
As a further improvement of the invention, the preparation method of the bacillus subtilis plasmin is as follows:
s1, preparing seed liquid; the strain Bacillus subtilis QK02 is stored in a low-temperature refrigerator at the temperature of-80 ℃, and is activated by a fresh inclined plane for 18-24 hours before use. Picking a ring of thallus from the inclined plane, inoculating the thallus into a triangular flask filled with LB liquid culture medium, and carrying out shaking culture on the thallus in a shaking table at the temperature of 35-40 ℃ and at the speed of 100-500r/min for 15-20h;
s2, fermentation culture: sterilizing the fermentation culture medium at 110-115 deg.C for 10-30min, cooling to room temperature, inoculating the seed solution into the fermentation culture medium according to 1% inoculation amount, and fermenting for 20-30 hr; wherein the temperature in the fermentation equipment is controlled to be 35-40 ℃, the humidity is controlled to be 80-90%, and the dissolved oxygen is 20-40%;
s3, post-processing: centrifuging the prepared fermentation liquor by a tubular centrifuge, performing microfiltration and ultrafiltration concentration to obtain a concentrated solution, and performing spray drying on the concentrated solution at the air inlet temperature of 120-150 ℃ and the air outlet temperature of 63-68 ℃ to obtain the bacillus subtilis fibrinolytic enzyme.
As a further improvement of the invention, the walnut kernel extract is an alcohol extract of walnut kernels.
Preferably, the walnut kernel extract is prepared by: crushing walnut kernels, wherein the material-liquid ratio is 1:10 adding 85% ethanol solution, reflux-extracting at 60 deg.C for 2-3 times (each time for 2-4 hr), hot filtering, mixing filtrates, and concentrating under reduced pressure to obtain alcohol-free extract as semen Juglandis extract
As a further improvement of the invention, the cordyceps militaris extract contains cordycepin.
Preferably, the cordyceps militaris extract is prepared by the following steps: pulverizing Cordyceps militaris, adding 8-20 times of water, extracting at 80-105 deg.C for 1-3 times for 2-6h, filtering the extractive solutions, mixing, concentrating to solid content of 5-25% to obtain Cordyceps militaris extract concentrate, and drying to obtain Cordyceps militaris extract.
As a further improvement of the invention, the haematococcus pluvialis comprises astaxanthin.
Preferably, the haematococcus pluvialis is prepared by: the Haematococcus pluvialis powder is prepared by taking Haematococcus pluvialis and spores as raw materials, stirring and breaking walls by a high-speed dispersion stirrer at 400-800 r/min, and drying by blowing at 60-80 ℃ until the moisture content is below 10%.
As a further improvement of the invention, the rice bran fatty alkanol comprises octacosanol.
As a further improvement of the invention, the composition further comprises acceptable auxiliary materials.
The invention further provides a preparation method of the composition for improving male reproductive capacity, which comprises the step of mixing bacillus subtilis fibrinolytic enzyme, haematococcus pluvialis, walnut kernel extract, cordyceps militaris extract and rice bran fatty alkanol in proportion to obtain the composition for improving male reproductive capacity.
Preferably, the composition for improving male reproductive capacity is prepared into one of capsules, tablets, powder and pills.
The invention further protects the application of the composition for improving male reproductive capacity in preparing foods, health-care foods and medicines for improving male reproductive capacity.
The bacillus subtilis fibrinolytic enzyme is prepared by taking soybean peptone as a raw material and performing bacillus subtilis liquid fermentation, concentration and drying, and contains various functional factors such as the bacillus subtilis fibrinolytic enzyme, vitamin K2 soybean short peptide and the like.
Haematococcus pluvialis is a freshwater unicellular green alga. The alga is named Haematococcus because it can accumulate a large amount of astaxanthin to give a red color. The astaxanthin content can reach 3.0% of dry weight, even higher, and the natural astaxanthin has the best biological source. The natural astaxanthin of Haematococcus pluvialis can enhance aerobic metabolism, reduce muscle pain, and improve endurance; reducing muscle damage and shortening recovery time; promote the fat burning and obtain higher energy level; maintaining joint function after strenuous exercise, and preventing obesity.
The walnut kernel is rich in a large amount of amino acids, crude protein and crude lipid, and is helpful for keeping the vitality of human body. In addition, the walnut kernel contains vitamin E which can protect cells from the oxidative damage of free radicals, and is an anti-aging substance recognized in the medical field.
The cordyceps militaris is neutral in nature and sweet in taste, beneficial to lung and kidney, capable of stopping bleeding and reducing phlegm, capable of treating deficiency and loss, rich in cordycepic acid, cordycepin, ergosterol and the like, and capable of tranquilizing and resisting various bacteria.
The rice bran fatty alkanol is prepared by saponifying rice bran wax prepared from rice bran, extracting, filtering and the like. The main components comprise fatty alcohol such as dioctadecyl fatty alkanol, triacontyl fatty alkanol, and dotriacontal fatty alkanol. Has effects in improving physical strength, enhancing endurance and energy, improving response sensitivity and stress, and improving metabolic rate. Therefore, the bacillus subtilis plasmin composition with reasonable compatibility is better adapted to the requirements of human bodies and has the effect of remarkably improving the male reproductive capacity, and when the components of the bacillus subtilis plasmin composition are matched for use, the dosage of the components alone or the combination of main functional components can be lower, so that the effect of exceeding the comprehensive effect and improving the single use of the components is achieved.
The invention has the following beneficial effects:
the bacillus subtilis plasmin composition with the effect of improving male reproductive capacity and the preparation method thereof provided by the invention have the advantages that medicinal and edible food materials are reasonably mixed, the remarkable synergistic effect is realized, the blood circulation and metabolism of a human body are promoted, the fatigue is eliminated, the androgen is supplemented, and the immunity of the human body is obviously improved.
Detailed Description
The technical solutions in the embodiments of the present invention will be clearly and completely described below, and it is obvious that the described embodiments are only a part of the embodiments of the present invention, and not all embodiments. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
The Bacillus subtilis QK02 strain is preserved in China center for type culture collection, the preservation place is Wuhan university in Wuhan, china, the preservation number is M203078, and the preservation date is 11/17/2003.
Example 1
A composition for improving male reproductive capacity and a preparation method thereof comprise the following steps:
1. preparation of bacillus subtilis fibrinolytic enzyme
(one) seed liquid preparation
The strain Bacillus subtilis QK02 is stored in a low-temperature refrigerator at the temperature of-80 ℃, and is activated for 24 hours by using a fresh inclined plane before use. A ring of thallus is picked from the inclined plane and inoculated into a triangular flask filled with LB liquid culture medium, and shaking cultured for 18h at 37 ℃ and 200r/min by a shaking table.
(II) fermentation culture in fermentation tank (500L)
Preparing a fermentation culture medium 300L shown in Table 1, sterilizing at 115 deg.C for 30min, cooling to room temperature, inoculating the seed solution into the fermentation culture medium according to 1% inoculation amount, and fermenting for 24h. Wherein the temperature, the humidity and the dissolved oxygen in the fermentation equipment are controlled to be 37 ℃, 85 percent and 30 percent respectively.
TABLE 1 culture Medium formulation
| Name (R) | Ratio of occupation of |
| Peptone | 2％ |
| Glucose | 2％ |
| Disodium hydrogen phosphate | 1％ |
| Sodium dihydrogen phosphate | 0.1％ |
| Magnesium sulfate | 0.05％ |
| Anhydrous calcium chloride | 0.02％ |
| Defoaming agent | 0.1％ |
| Deionized water | Balance of |
(III) preparation of bacillus subtilis fibrinolytic enzyme
After fermentation, the fermentation liquor is centrifuged by a tubular centrifuge, and after microfiltration and ultrafiltration concentration, about 25L of concentrated solution is obtained. Spray drying the concentrated solution at the air inlet temperature of 140 ℃ and the air outlet temperature of 65 ℃ to obtain the bacillus subtilis fibrinolytic enzyme.
2. Preparation of haematococcus pluvialis: the Haematococcus pluvialis powder is prepared by taking Haematococcus pluvialis and spores as raw materials, stirring and breaking walls by a high-speed dispersion stirrer at 600r/min, and drying by blowing at 75 ℃ until the moisture content is 8%.
3. Preparation of the walnut kernel extract: crushing walnut kernels, wherein the material-liquid ratio is 1:10 adding 85% ethanol solution, reflux-extracting at 60 deg.C for 3 times (each time for 3 hr), hot-filtering, mixing filtrates, and concentrating under reduced pressure to obtain alcohol-free extract, i.e. semen Juglandis extract.
4. Preparation of cordyceps militaris extract: pulverizing Cordyceps militaris, adding 12 times of water, extracting at 90 deg.C for 2 times, extracting for 4h, filtering the extractive solutions, mixing, concentrating to solid content of 18% to obtain Cordyceps militaris extract concentrate, and drying to obtain Cordyceps militaris extract.
5. After the raw materials are sieved by a sieve of 80 meshes, the composition is prepared by mixing 20 parts of bacillus subtilis fibrinolytic enzyme, 10 parts of haematococcus pluvialis, 5 parts of walnut kernel extract, 5 parts of cordyceps militaris extract and 0.4 part of rice bran fatty alkanol.
Example 2
Compared with the example 1, the raw material proportion is different.
The raw materials comprise the following components in parts by weight: 10 parts of bacillus subtilis fibrinolytic enzyme, 5 parts of haematococcus pluvialis, 3 parts of walnut kernel extract, 3 parts of cordyceps militaris extract and 0.3 part of rice bran fatty alkanol.
Example 3
Compared with the example 1, the raw material proportion is different.
The raw materials comprise the following components in parts by weight: 30 parts of bacillus subtilis fibrinolytic enzyme, 15 parts of haematococcus pluvialis, 10 parts of walnut kernel extract, 10 parts of cordyceps militaris extract and 0.5 part of rice bran fatty alkanol.
Comparative example 1
Compared to example 1, only subtilisin plasmin was included.
The raw materials comprise: bacillus subtilis fibrinolytic enzyme.
Comparative example 2
Compared with the example 1, the bacillus subtilis plasmin is not contained, and the other components have unchanged distribution ratio.
The raw materials comprise the following components in parts by weight: 15 parts of haematococcus pluvialis, 10 parts of walnut kernel extract, 10 parts of cordyceps militaris extract and 0.5 part of rice bran fatty alkanol.
Experimental example 1 test for spermatogenic dysfunction due to kidney-yang deficiency
Establishing a kidney-yang deficiency rat model: the rats are intramuscularly injected with 10 mg/mouse of hydrocortisone injection every day for 2 weeks continuously to form a kidney-yang deficiency model, and after the model is made, the rats are frightened, warm, cold limbs, clear and long urine, tired and contracted dorsum, mao Moguang and are scattered, listened and emaciated and accord with the symptoms of kidney-yang deficiency, namely the model is successfully built.
Animal grouping and administration method: normal rats are used as a blank control group, the obtained kidney-yang deficiency rat model is used as a model group, 3 experimental groups and 2 comparison groups, and each group comprises 20 rats. The experimental group was administered with the male fertility improving composition prepared in examples 1 to 3, and the comparative group was administered with the male fertility improving composition prepared in comparative examples 1 to 2, each at a dose of 1.5g/Kg, 2 times daily for 4 weeks. The blank control group and the model group were not administered. Wet weights of left testis, spleen and thymus were measured after 4 weeks for each group of animals; detecting the levels of testosterone (T), luteinizing Hormone (LH) and Follicle Stimulating Hormone (FSH) in serum; percent sperm motility and sperm density.
As a result: (1) The results of the effect on the wet weights of the testis, spleen and thymus in the left side of the model rat are shown in Table 2.
TABLE 2 Wet weight determination of left testis, spleen and thymus in rats of each group
Note: * P <0.05, P <0.01vs model group
As can be seen from table 2, after the model rats were treated with the drug for 2 weeks, the wet weights of the left testis, spleen and thymus in each drug group increased more or less than those in the model group, and the wet weights of the left testis and spleen in the composition test group increased significantly. The results show that the composition for improving male reproductive capacity and the bacillus subtilis plasmin in the examples 1-3 are beneficial to the recovery of the reproductive organs of rats with kidney-yang deficiency, and the effect of the composition in the examples 1-3 is superior to that of the bacillus subtilis plasmin in the comparative example 1, which shows the synergistic effect of the raw materials.
As a result: (2) The results of the effects on serum T, LH, FSH levels in model rats are shown in Table 3.
TABLE 3 serum T, LH, FSH levels results for various groups of rats
| Group of | T(ng/dL) | LH(mIU/ml) | FSH(mIU/ml) |
| Control group | 28.96±3.63 | 9.36±2.24 | 11.26±2.09 |
| Model set | 20.27±3.58 | 6.68±2.17 | 8.13±1.75 |
| Comparative example 1 group | 23.68±3.26 | 8.27±2.06 | 9.86±2.13 * |
| Comparative example 2 group | 20.88±3.42 | 7.06±1.87 | 8.47±1.59 |
| EXAMPLE 1 group | 26.77±3.86 * | 8.85±1.89 * | 10.24±1.78 * |
| EXAMPLE 2 group | 25.64±3.56 | 8.52±1.63 | 10.03±1.42 |
| EXAMPLE 3 group | 27.32±3.47 * | 9.05±1.91 ** | 10.88±1.86 * |
Note: * P <0.05, P <0.01vs model group.
As can be seen from the results in table 3, the levels of serum T, LH and FSH of rats in each group increased compared to those of the model group, wherein the FSH content of the bacillus subtilis plasmin experimental group was significantly increased, and the T, LH and FSH content of the composition experimental group was significantly increased. The result shows that the composition in the example 3 has a remarkable effect on the generation of the sex hormone of the rat with the deficiency of the kidney-yang due to the synergistic effect.
As a result: (3) The results of the effect on the sperm motility and sperm density of model rats are shown in Table 4.
TABLE 4 results of sperm motility and sperm density of rats in each group
| Group of | Sperm motility (%) | Sperm density (. 10) 6 /ml) |
| Control group | 86.42±8.09 | 74.12±9.21 |
| Model set | 30.58±7.22 | 23.74±7.34 |
| Comparative example 1 group | 67.52±6.83 | 58.55±9.82 |
| Comparative example 2 group | 32.46±6.58 | 22.84±6.65 |
| EXAMPLE 1 group | 82.21±6.82 | 71.23±8.36* |
| EXAMPLE 2 group | 79.35±7.54 | 70.57±8.65 |
| EXAMPLE 3 group | 83.66±7.79* | 72.31±9.05** |
Note: * P <0.05, P <0.01vs model group.
The results in table 4 show that the sperm motility and sperm density of the rats in each group are improved compared with those of the rats in the model group, and the sperm motility and sperm density of the rats in the composition experimental group are obviously improved and are close to the level of the control group. The results show that the effect of the compositions in examples 1-3 is superior to that of the bacillus subtilis plasmin in comparative example 1, and the synergistic effect is obvious in improving the number of sperms and the survival rate of rats with kidney-yang deficiency.
Experimental example 2 experiment on the development of the genitalia of immature male rats
2 months old S.D male rats are taken, and the weight is 75-85g. The total amount of the components is 2 groups (20 in each group). The control group was fed normally, the experimental group was fed continuously with the composition prepared in examples 1 to 3 for 2 weeks, and the control group was fed continuously with the composition prepared in comparative examples 1 to 2 for 2 weeks, each dose being set to 0.7g/Kg, 2 times a day. After 2 weeks the animals were sacrificed and the wet weight of testis, epididymis, adenohypophysis and seminal vesicle was weighed.
As a result: the results of the effect of the composition for improving male fertility on the development of the genitalia of immature male rats are shown in table 5.
TABLE 5 Male rat genital development results
Note: * P <0.05, P <0.01vs control group.
As can be seen from the results in Table 5, the composition for improving male fertility accelerates the development of genital testis, epididymis, adenohypophysis, and seminal vesicle in immature male rats, compared to the control group. The results show that the synergistic effect of the compositions in examples 1-3 is significant in promoting the development of testis, epididymis and seminal vesicle in immature male rats.
And (4) conclusion: the bacillus subtilis fibrinolytic enzyme has positive effects on improving the recovery of reproductive organs of rats with kidney-yang deficiency, the production of androgen and the survival rate of sperms, and can also promote the development of the reproductive organs of immature male rats. The composition of the bacillus subtilis fibrinolytic enzyme, haematococcus pluvialis, walnut kernel extract, cordyceps militaris extract and rice bran fatty alkanol which are matched and combined can realize synergistic interaction, remarkably improve the reproductive capacity of male rats with kidney-yang deficiency, promote the development of reproductive organs of immature male rats, and has good application prospect in the development of functional products for improving the male reproductive capacity.
The above description is only for the purpose of illustrating the preferred embodiments of the present invention and should not be taken as limiting the scope of the present invention, which is intended to cover any modifications, equivalents, improvements, etc. within the spirit and scope of the present invention.
Claims (10)
1. The composition for improving male reproductive capacity is characterized by being prepared from the following raw materials in parts by weight: 10-30 parts of bacillus subtilis fibrinolytic enzyme, 5-15 parts of haematococcus pluvialis, 3-10 parts of walnut kernel extract, 3-10 parts of cordyceps militaris extract and 0.3-0.5 part of rice bran fatty alkanol; the Bacillus subtilis fibrinolytic enzyme is prepared by fermenting a strain Bacillus subtilis QK02, the strain is preserved in China center for type culture collection with the preservation number of CCTCC NO: M203078.
2. The composition for improving male fertility according to claim 1, wherein the Bacillus subtilis plasmin is prepared by fermenting Bacillus subtilis QK02 strain, centrifuging, concentrating and drying.
3. The composition for improving male reproductive performance according to claim 1, wherein the bacillus subtilis plasmin is prepared by the following steps:
s1, preparing seed liquid; the strain Bacillus subtilis QK02 is stored in a low-temperature refrigerator at the temperature of-80 ℃, and is activated by a fresh inclined plane for 18-24 hours before use. Picking a ring of thallus from the inclined plane, inoculating the thallus into a triangular flask filled with LB liquid culture medium, and carrying out shaking culture on the thallus in a shaking table at the temperature of 35-40 ℃ and at the speed of 100-500r/min for 15-20h;
s2, fermentation culture: sterilizing the fermentation culture medium at 110-115 deg.C for 10-30min, cooling to room temperature, inoculating the seed solution into the fermentation culture medium according to 1% inoculation amount, and fermenting for 20-30 hr; wherein the temperature in the fermentation equipment is controlled to be 35-40 ℃, the humidity is controlled to be 80-90%, and the dissolved oxygen is 20-40%;
s3, post-processing: centrifuging the prepared fermentation liquor by a tubular centrifuge, performing microfiltration and ultrafiltration concentration to obtain a concentrated solution, and performing spray drying on the concentrated solution at the air inlet temperature of 120-150 ℃ and the air outlet temperature of 63-68 ℃ to obtain the bacillus subtilis fibrinolytic enzyme.
4. The composition for improving male reproductive performance of claim 1 wherein the extract of walnut kernel is an alcohol extract of walnut kernel.
5. The composition for improving male reproductive capacity as claimed in claim 1, wherein the extract of cordyceps militaris comprises cordycepin.
6. The composition for improving male reproductive performance according to claim 1 wherein the Haematococcus pluvialis comprises astaxanthin.
7. The composition for improving male reproductive performance of claim 1 wherein the rice bran fatty alkanol comprises octacosanol.
8. The composition for improving male reproductive performance according to claim 1 further comprising an acceptable excipient.
9. A method of preparing a composition for improving male fertility according to any one of claims 1 to 8, wherein the composition for improving male fertility is prepared by mixing bacillus subtilis plasmin, haematococcus pluvialis, walnut kernel extract, cordyceps militaris extract and rice bran fatty alkanol in proportion.
10. Use of a composition for improving male reproductive ability according to any one of claims 1 to 8 in the manufacture of a food, health food or pharmaceutical product for improving male reproductive ability.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211081171.2A CN115252768A (en) | 2022-09-06 | 2022-09-06 | Composition for improving male reproductive capacity, preparation method and application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211081171.2A CN115252768A (en) | 2022-09-06 | 2022-09-06 | Composition for improving male reproductive capacity, preparation method and application |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN115252768A true CN115252768A (en) | 2022-11-01 |
Family
ID=83757160
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202211081171.2A Pending CN115252768A (en) | 2022-09-06 | 2022-09-06 | Composition for improving male reproductive capacity, preparation method and application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115252768A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111870689A (en) * | 2020-08-12 | 2020-11-03 | 武汉真福医药股份有限公司 | Application of nattokinase in medicine for treating osteoporosis |
-
2022
- 2022-09-06 CN CN202211081171.2A patent/CN115252768A/en active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111870689A (en) * | 2020-08-12 | 2020-11-03 | 武汉真福医药股份有限公司 | Application of nattokinase in medicine for treating osteoporosis |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101760478B (en) | Preparation method of radix puerariae red yeast rice | |
| KR101228993B1 (en) | Fermentation and culture method, fermented plant extract, fermented plant extract powder and composition containing the fermented plant extract | |
| CN103710236B (en) | A kind of preparation method of maca nutritional wine | |
| CN102499291B (en) | Milk powder with functions of maintaining beauty and keeping young and improving immunity of organism and preparation method thereof | |
| CN104352552B (en) | A kind of food, health products or pharmaceutical composition | |
| CN115252768A (en) | Composition for improving male reproductive capacity, preparation method and application | |
| CN101664180B (en) | Health-care nutritional complexing agent with health effect and preparation method thereof | |
| WO1999021961A1 (en) | Process for making and uses of cordyceps fermentation products | |
| CN108618128A (en) | Adjust the composition and its preparation method and application of immunity | |
| CN102934769B (en) | Bee pollen mixture buccal tablet for alleviating hangovers | |
| CN106924548A (en) | The medicine and preparation method of a kind of fatigue-relieving | |
| CN112617196A (en) | Food, health-care product or pharmaceutical composition for resisting anoxia and fatigue and preparation method and application thereof | |
| CN116076710A (en) | Rose herbal ferment with anti-aging and whitening functions and preparation method and application thereof | |
| CN110731503A (en) | Ginseng, fructus Lycii and Cordyceps tablet, and its preparation method | |
| CN102511876A (en) | Hawthorn red jujube thick syrup | |
| CN112076292A (en) | Powder with functions of enhancing immunity and regulating kidney yin deficiency and preparation method thereof | |
| CN106389477A (en) | Preparation method and application of whole-cell vegetable oil extracts of gordona terrae | |
| CN114010750A (en) | Ginseng and grass formula for tonifying kidney, generating blood and resisting aging | |
| CN108379446B (en) | Coenzyme Q10 preparation for adjuvant treatment of male oligospermia and preparation method thereof | |
| CN102511882A (en) | Red jujube thick syrup beneficial for improving growth and development | |
| CN112352945A (en) | Artificial cordyceps militaris food with effects of resisting fatigue and improving immunity | |
| CN112043730A (en) | Traditional Chinese medicine biological preparation for preventing and treating animal epidemic diseases | |
| CN1314340C (en) | Method for preparing milk powder contg. micron sang, white fungus and oligose for face-beauty, toning-lungs and lowering blood-sugar | |
| CN1298229C (en) | Method for preparing milk pellets contg. micro sang, white fungus and oligose for face-beauty, toning-lungs and lowering blood-sugar | |
| CN113100442B (en) | Royal jelly tortoise turtle peptide chewing tablet and preparation process thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |